Botulinum toxin in the management of chronic migraine: clinical evidence and experience. (February 2017)

• Record Type: Journal Article
• Authors: Escher, Claus M; Paracka, Lejla; Dressler, Dirk; Kollewe, Katja
• Is Part Of: Therapeutic advances in neurological disorders. Volume 10:Number 2(2017:Mar.)
• Page Start: 127
• Page End: 135
• Publication Date: 2017-02
• Subjects: Botox® -- botulinum neurotoxin -- chronic daily headache -- chronic migraine -- onabotulinumtoxinA; Nervous system -- Diseases -- Periodicals; Nervous system -- Degeneration -- Periodicals; Nervous system -- Diseases -- Treatment -- Periodicals; Nervous System Diseases -- therapy -- Periodicals; Neurodegenerative Diseases -- Periodicals; Système nerveux -- Maladies -- Périodiques; Système nerveux -- Dégénérescence -- Périodiques; Système nerveux; Système nerveux -- Maladies -- Traitement -- Périodiques; 616.805
• DOI: 10.1177/1756285616677005
• Languages: English
• ISSNs: 1756-2856

Abstract

Chronic migraine (CM) is a severely disabling neurological condition characterized by episodes of pulsating unilateral or bilateral headache. The United States Food and Drug Administration (FDA) approved onabotulinumtoxinA (Botox ® ) for the prophylactic treatment of CM in 2010. It has been shown that onabotulinumtoxinA is effective in the reduction of headache frequency and severity in patients with CM. Treatment is well tolerated by the patients. This review reports on the history of botulinum neurotoxin (BoNT) in CM and presents the current clinical evidence for the use of onabotulinumtoxinA in the treatment of CM.